Ask about this productRelated genes to: SSTR2 antibody
- Gene:
- SSTR2 NIH gene
- Name:
- somatostatin receptor 2
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 17q25.1
- Locus Type:
- gene with protein product
- Date approved:
- 1992-08-25
- Date modifiied:
- 2016-10-25
Related products to: SSTR2 antibody
Related articles to: SSTR2 antibody
- - Source: PubMed
Publication date: 2026/04/28
Fischer AlessaMaccio UmbertoInukai Junko InoueZitzmann KathrinAuernhammer Christoph JHantel ConstanzeRobledo MercedesVölter FriederikeHüllner MartinGrossman Ashley BPacak KarelBeuschlein FelixHuber AlexanderBeintner-Skawran StephanNölting Svenja - Cerebrospinal fluid-contacting neurons (CSF-cNs) are mechanosensory cells in the spinal cord that detect compression and regulate locomotion, posture, and morphogenesis. Although CSF-cNs respond to changes in pH, neurotransmitters and metabolites, their chemosensory repertoire is not fully understood. Using hybridization chain reaction, we investigated the distribution of expression of chemoreceptors in CSF-cNs and neighboring cells in the spinal cord. We found that CSF-cNs express receptors for glutamate ( ), somatostatin ( ) and low-density lipoprotein (LDL) (ldlrad2), indicating roles in detecting glutamate, somatostatin and LDL in the CSF. High LDL receptor expression in CSF-contacting cells suggests CSF lipid capture. Most receptors were enriched but not exclusive to CSF-cNs and also appeared in ependymal radial glial cells. Our findings indicate multiple chemosensory pathways can sustain long-distance communication between neurons and glia through the cerebrospinal fluid. - Source: PubMed
Publication date: 2026/04/16
Verran EmilyMoizan LouiseTocquer LoevaQuan Feng BWyart Claire - Breast cancer (BC) is a biologically heterogeneous disease, and no single imaging modality captures the full spectrum of phenotypes across all stages of the disease. This review summarizes advances in receptor-targeted nuclear imaging approaches that support patient stratification, treatment selection and response monitoring. - Source: PubMed
Publication date: 2026/04/26
Paraïso Pvan Deurzen C H MSeimbille Y - Over the past decade, positron emission tomography (PET) has become an important part of the management of large-vessel vasculitis (LVV). Current clinical practice relies predominantly on [18F]fluorodeoxyglucose ([18F]FDG) PET combined with computed tomography (CT) for anatomical localisation. Although [18F]FDG PET/CT shows high specificity and good sensitivity for primary diagnosis, persistent vascular uptake during clinical remission limits its specificity for relapse assessment and complicates longitudinal monitoring. Alongside technological advances in PET hardware, an expanding portfolio of alternative radiotracers has emerged to probe more specific inflammatory pathways and cell-associated processes.This narrative review summarises the most informative clinical evidence currently available for novel PET tracers in giant cell arteritis (GCA) and Takayasu's arteritis (TAK). Targets related to immune cell recruitment and vascular inflammation include the vascular adhesion protein-1 (VAP-1)/sialic-acid-binding immunoglobulin-like lectin-9 (Siglec-9) axis, assessed by [68Ga] Ga-DOTA-Siglec-9. Similarly, C-X-C chemokine receptor 4 (CXCR4) imaging with [68Ga]PentixaFor has been explored as an approach to capture chemokine-mediated immune cell trafficking. For the assessment of myeloid activation, somatostatin receptor subtype 2 (SSTR2) imaging using [68Ga] DOTATATE or [18F]FET-βAG-TOCA has been explored as an approach to differentiate active from inactive disease. Imaging of the 18 kDa translocator protein (TSPO), a mitochondrial outer membrane protein associated with cellular stress and myeloid activation, seeks to provide a complementary inflammation- and stress-related read-out, although its clinical applicability is influenced by ligand-specific performance and genotype-dependent binding. Finally, fibroblast activation protein (FAP)-targeted PET with fibroblast activation protein inhibitors (FAPI, e.g. [68Ga]-FAPI-46) has been investigated to visualise fibroblast activation and vascular remodelling, with persistent uptake during clinical remission potentially indicating ongoing tissue repair or structural remodelling. - Source: PubMed
Publication date: 2026/04/22
Petzinna Simon MBauer Claus-JürgenSchäfer Valentin S - Neuroendocrine neoplasms (NENs) represent heterogeneous tumors with increasing occurrence rate. Somatostatin receptor (SSTR) imaging using Ga-labeled analogs is crucial but limited by the relatively short half-life of this radionuclide along with its reliance on generator supply. To overcome these limitations, this study aimed to establish an automated synthesis platform compliant with Good Manufacturing Practice (GMP) standards for the preparation of a novel SSTR-targeting probe, [F]AlF-NOTA-octreotide. Its diagnostic efficacy in neuroendocrine neoplasms was evaluated through comparison with existing Ga-labeled and [F]FDG probes. - Source: PubMed
Publication date: 2026/04/21
Wan XiaotingYan JiangyueHu JietingZhang RuiyunZhu ShiliangSun HaoCao JingwenLi KaixuanYang DacanYang LingyunXianyu KaizhenXia DiHe ZijianLi Dan